Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos


RETAIN-2 neoadjuvant AMVAC + nivolumab: NCT04506554 enrolling @sonpavde https://t.co/veCUbnuAGZ

  • 123456 Profile photo of Madelyn

    The RETAIN-2 neoadjuvant aMVAC + nivolumab (NCT04506554) trial is following RETAIN (Geynisman et al.) & HCRN trial (Galsky et al.) (both were presented at GU ASCO ’23) in the attempt to assess bladder preservation in localized MIBC. Prospective evaluation of biomarkers in trials is key, but we need more work in biomarker validation.